Glycolysis

Scientific explanation

Aerobic (Warburg metabolism) supports ATP, biomass and redox buffering even when oxygen is available. Hexokinase, PKM2 and lactate export are frequent nodes.

Cancers where relevant

Breast cancer ER+ breast cancer HER2+ breast cancer Triple-negative breast cancer Lung cancer Non-small-cell lung cancer Small-cell lung cancer KRAS-driven NSCLC Mesothelioma Colorectal cancer KRAS-mutant colorectal cancer Pancreatic cancer Gastric cancer Esophageal cancer Hepatocellular carcinoma Liver cancer Cholangiocarcinoma Ovarian cancer Cervical cancer Endometrial cancer Prostate cancer Neuroendocrine prostate cancer Kidney / renal cell carcinoma Bladder cancer Testicular cancer Acute myeloid leukemia Acute lymphoblastic leukemia Non-Hodgkin lymphoma Multiple myeloma Brain tumors Glioblastoma IDH-mutant glioma IDH-wildtype glioma Melanoma Head and neck cancers Thyroid cancer Neuroendocrine tumors Sarcomas Bone cancers

Compounds that intersect this pathway

Metformin

Modest complex I inhibition raises AMP:ATP, activating and restraining hepatic and -linked anabolism. Direct antineoplastic efficacy is not established from that pharmacology alone.

Evidence in mapped cancers: Clinical / Human Evidence · In Vivo · In Vitro · Mechanistically Plausible

Mebendazole

Benzimidazole that binds β-. Mammalian disruption, mitotic arrest and related signalling in cancer models are preclinical and are not an approved anticancer use.

Fenbendazole

Veterinary benzimidazole with and experimental glucose-transport effects in cell models. Not an established human antineoplastic.

Evidence in mapped cancers: In Vitro · Hypothesis-Generating

Albendazole

Benzimidazole anthelmintic with effects; mammalian oncology readouts remain preclinical.

AICAR

AMP mimetic that activates in experimental systems. Research tool, not an approved oncology medicine.

Berberine

Isoquinoline alkaloid that can inhibit complex I and activate in metabolic models, with additional -independent reports. Not an approved antineoplastic.

Convergence partners

Other pathways that co-occur with Glycolysis on mapped adjunct records: AMPK, mTOR, Apoptosis.

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.